其他
儿童实体瘤又一新药获批,恩曲替尼让孩子看见曙光
编译 | 严青
责编 | 依伊
排版 | 良胤
校对 | 良胤
参考文献:
1. FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK GeneFusion-Positive Solid Tumors. August 15th, 2019.https://www.gene.com/media/press-releases/14802/2019-08-15/fda-approves-genentechs-rozlytrek-entrec2. Genentech’s Personalized Medicine Entrectinib ShrankTumors Harboring NTRK, ROS1 Or ALK Gene Fusions in Children and Adolescents. May 15th, 2019.https://www.gene.com/media/press-releases/14791/2019-05-15/genentechs-personalized-medicine-entrect
点一次“在看”,就是说一声“加油孩子们!”